

Non-Opioid Pain Management Options Provider Guide

Drug	Indication as It Relates to Pain	Pain Dosing	Titration	Formulary	Abuse Potential		
Analgesic Class	Analgesic Class						
Acetaminophen	FDA Uses pain (mild to severe) Non-FDA Uses osteoarthritis	Maximum daily dose for adults Over 50kg: 4000mg divided as 650mg every 4 hours or 1000mg every 6 hours Less than 50kg: maximum daily dose 75mg/kg (3750mg/d) divided as 12.5mg/kg every 4 hours or 15mg/kg every 6 hours	No titration	C OTC MK OTC M OTC MD OTC	Minimal		
NSAIDs Class							
lbuprofen*	FDA Uses pain, osteoarthritis, rheumatoid arthritis	Suggested dose: 1200–3200mg divided Maximum daily dose: 3200mg divided	No titration	C Tier 1 MK Tier 1 M Tier 1 MD Tier 2	Minimal		
Naproxen*	FDA Uses ankylosing spondylitis, bursitis, acute gout, osteoarthritis, pain, rheumatoid arthritis, acute tendinitis Non-FDA Uses soft tissue injury	Initial dose: 250–500mg twice daily Maximum daily dose: 1500mg for limited periods up to 6 months Naproxen sodium salt is more rapidly absorbed so it is recommended for relief of acute pain Initial dose: 275–550mg twice daily Maximum daily dose: 1650mg for limited periods up to 6 months	No titration	C Tier 1 MK Tier 1 M Tier 1 MD Tier 2	Minimal		
Celecoxib*	FDA Uses ankylosing spondylitis, rheumatoid arthritis, osteoarthritis, acute pain Non FDA Uses acute gout, acute postoperative pain	Initial dose: 400mg once daily and additional 200mg once daily as needed Maintenance: 200mg twice daily as needed	No titration	C Tier 1 MK Tier 2 M Tier 1 MD Tier 3	Minimal		

Drug	Indication as It Relates to Pain	Pain Dosing	Titration	Formulary	Abuse Potential		
NSAIDs Class contin	NSAIDs Class continued						
Diclofenac 1% gel	FDA Uses ankylosing spondylitis, osteoarthritis, pain, rheumatoid arthritis	4g to lower extremities 4 times a day, 2g to upper extremities 4 times a day Maximum doses: 8mg/d for single joint upper extremity, 16g/d for single joint lower extremity, 32g/d total over all joints affected	No titration	C Tier1 MK Tier2 M Tier1 MD Tier3	Minimal		
Anticonvulsants Cla	ass						
Gabapentin	FDA Uses postherpetic neuralgia FDA Uses diabetic peripheral neuropathy, fibromyalgia, postoperative pain	Initial dose: 300mg/d Target: 1800–2400mg/d divided	Titrate by 300mg every 3 days	C Tier1 MK Tier1 M Tier1 MD Tier2	C5 in Kentucky Ohio, Massachusetts, Minnesota reported on PMP equivalent Withdrawal symptoms have occurred		
Lyrica	FDA Uses diabetic peripheral neuropathy, fibromyalgia, neuropathic pain (spinal cord injury), postherpetic neuralgia Non-FDA Uses postoperative pain, restless legs syndrome	Initial dose: 150mg/d divided Target: 600mg/d divided	Titrate by 150mg every 7 days	C Tier3 MK Tier3 M Tier2 MD Tier3QL	C5 nationally		
SNRI Antidepressants Class							
Duloxetine	FDA Uses diabetic peripheral neuropathy, fibromyalgia, musculoskeletal pain (chronic) Non-FDA Uses chemotherapy-induced pain (peripheral nerve disease)	Initial dose: 300mg/d Target: 60mg/d	Titrate by 30mg after the first week	C Tier 1 MK Tier 2 M Tier 1 MD Tier 3	Withdrawal symptoms occur in about 50% of patients who stop this medication		

Drug	Indication as It Relates to Pain	Pain Dosing	Titration	Formulary	Abuse Potential	
SNRI Antidepressants Class continued						
Venlafaxine	Non-FDA Uses diabetic neuropathy	Initial dose: 37.5mg/d Target: 225mg/d	Titrate by 37.5mg in the first week, then increase by 75mg weekly	C Tier 1 MK Tier 1 M Tier 1 MD Tier 2/3	SSRI-like withdrawal symptoms when abruptly stopped	
Tricyclic Antidepre	ssants Class					
Amitriptyline*	Non-FDA Uses fibromyalgia, headache (treatment/prophylaxis), pain, postherpetic neuralgia	Initial dose: 25mg/d Target: 100mg/d	Titrate by 25mg intervals every 3–5 days	C Tier1 MK Tier1 M Tier1 MD PA	Withdrawal symptoms such as nausea, headache, insomnia, or anxiety	
Nortriptyline*	Non-FDA Uses diabetic neuropathy, postherpetic neuralgia	Initial dose: 10mg/d Target: 100mg/d	Titrate in 10mg intervals every 3–5 days	C Tier 1 MK Tier 1 M Tier 1 MD Tier 2	Withdrawal symptoms such as nausea and headache	
Desipramine*	Non-FDA Uses diabetic neuropathy, postherpetic neuralgia	25–150mg/d can be divided	No titration	C Tier1 MK Tier1 M Tier1 MD Tier2	Withdrawal symptoms such as nausea, headache, insomnia, or anxiety	
Local Anesthetic Class						
Lidocaine patch	FDA Uses local anesthesia, postherpetic neuralgia Non-FDA Uses diabetic neuropathy	Apply 1–3 patches to painful area, on for 12 hours, then off for 12 hours	No titration	C Tier 1 MK Tier 2 M PA MD Tier 3 PA	Minimal	

Drug	Indication as It Relates to Pain	Pain Dosing	Titration	Formulary	Abuse Potential	
Muscle Relaxants, Centrally Acting Class						
Baclofen 10mg and 20mg	FDA Uses spasticity Non-FDA Uses trigeminal neuralgia	Initial dose: 5mg 3 times a day Maximum dose: 80mg per day divided	15mg per day, increments every 3 days	C Tier 1 MK Tier 1 M Tier 1 MD Tier 2	Experimentally used to treat alcohol and drug addiction Sudden discontinuation can lead to side effects such as anxiety and confusion, psychosis, convulsions, and tachycardia	
Chlorzoxazone*	FDA Uses musculoskeletal pain	500–700mg 3–4 times daily	No titration	C Tier 1 MK Tier 1 M Tier 1 MD NF	Possible respiratory depression when combined with benzodiazepines, barbiturates, codeine or its derivatives, or other muscle relaxants	
Cyclobenzaprine*	FDA Uses skeletal muscle spasm, acute Non-FDA Uses fibromyalgia	Initial dose: 5mg orally 3 times per day Maximum dose: 10mg orally 3 times per day for no longer than 2–3 weeks Fibromyalgia dosing: 10–30mg every night	Increase as needed	C Tier 1 MK Tier 1 M Tier 1 MD NF	Minimal	
Metaxalone*	FDA Uses musculoskeletal pain	800mg orally 3–4 times a day	No titration	C Tier 1 MK Tier 2 M NF MD Tier 4	Possible respiratory depression when combined with benzodiazepines, barbiturates, codeine or its derivatives, or other muscle relaxants	

Drug	Indication as It Relates to Pain	Pain Dosing	Titration	Formulary	Abuse Potential
Muscle Relaxants, 0	Centrally Acting Class continued				
Methocarbamol*	FDA Uses musculoskeletal pain	Initial dose: 1500mg orally 4 times a day for 48–72 hours; 8g per day may be administered for severe conditions Maintenance: 750mg orally every 4 hours, 1500mg 3 times a day, or 1000mg 4 times a day	No titration	C Tier 1 MK Tier 1 M Tier 1 MD NF	Possible respiratory depression when combined with benzodiazepines, barbiturates, codeine or its derivatives, or other muscle relaxants
Tizanidine Tablets	FDA Uses spasticity Non-FDA Uses acute pain	Initial dose: 2mg orally may repeat every 6–8 hours to a maximum of 3 doses a day Maximum dose: 36mg per day	Increase by 2–4mg per dose at 1–4 day intervals	C Tier 1 MK Tier 1 M Tier 1 MD Tier 2	Minimal
Muscle Relaxants, I	Peripherally Acting Class				
Dantrolene	FDA Uses spasticity, chronic	Initial dose: 25mg once daily for 7 days Maximum dose: 100mg 4 times a day	After first 7 days, use 25mg 3 times a day for 7 days, then 50mg 3 times a day for 7 days, then 100mg 3 times a day	C Tier 1 MK Tier 2 M Tier 1 MD NF	Minimal

References

- 1. http://www.pharmacytimes.com/publications/health-system-edition/2016/march2016/neuropathic-pain
- 2. Micromedex
- 3. Package inserts
- 4. https://immunalysis.com/wp-content/uploads/2015/06/Drug_Test_Poster_24X39_89093_REV3.pdf
- 5. https://americanaddictioncenters.org/addiction-medications/baclofen
- 6. https://www.aafp.org/afp/2008/0801/p365.html